TY - JOUR
T1 - Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors
T2 - A Report from the Center for International Blood and Marrow Transplant Research
AU - Buchbinder, David
AU - Brazauskas, Ruta
AU - Bo-Subait, Khalid
AU - Ballen, Karen
AU - Parsons, Susan
AU - John, Tami
AU - Hahn, Theresa
AU - Sharma, Akshay
AU - Steinberg, Amir
AU - D'Souza, Anita
AU - Kumar, Anita J.
AU - Yoshimi, Ayami
AU - Wirk, Baldeep
AU - Shaw, Bronwen
AU - Freytes, César
AU - LeMaistre, Charles
AU - Bredeson, Christopher
AU - Dandoy, Christopher
AU - Almaguer, David
AU - Marks, David I.
AU - Szwajcer, David
AU - Hale, Gregory
AU - Schouten, Harry
AU - Hashem, Hasan
AU - Schoemans, Hélène
AU - Murthy, Hemant S.
AU - Lazarus, Hillard M.
AU - Cerny, Jan
AU - Tay, Jason
AU - Yared, Jean A.
AU - Adekola, Kehinde
AU - Schultz, Kirk R.
AU - Lehmann, Leslie
AU - Burns, Linda
AU - Aljurf, Mahmoud
AU - Diaz, Miguel Angel
AU - Majhail, Navneet
AU - Farhadfar, Nosha
AU - Kamble, Rammurti
AU - Olsson, Richard
AU - Schears, Raquel
AU - Seo, Sachiko
AU - Beattie, Sara
AU - Chhabra, Saurabh
AU - Savani, Bipin N.
AU - Badawy, Sherif
AU - Ganguly, Siddhartha
AU - Ciurea, Stefan
AU - Marino, Susana
AU - Gergis, Usama
AU - Kuwatsuka, Yachiyo
AU - Inamoto, Yoshihiro
AU - Khera, Nandita
AU - Hashmi, Shahrukh
AU - Wood, William
AU - Saber, Wael
N1 - Funding Information:
Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Financial disclosure: See Acknowledgments on page 560.
Funding Information:
Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo.
Publisher Copyright:
© 2019 American Society for Transplantation and Cellular Therapy
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/3
Y1 - 2020/3
N2 - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.
AB - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.
KW - Bone marrow transplantation
KW - Lost to follow-up
KW - Stem cell transplantation
KW - Survivor
UR - http://www.scopus.com/inward/record.url?scp=85076525725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076525725&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2019.11.003
DO - 10.1016/j.bbmt.2019.11.003
M3 - Article
C2 - 31726205
AN - SCOPUS:85076525725
VL - 26
SP - 553
EP - 561
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 3
ER -